Boston Scientific Q1 Earnings Preview: Diving Deeper Than Headline Estimates

Analysts project key metrics for the medical device company beyond just top and bottom line numbers.

Apr. 17, 2026 at 2:38pm

Got story updates? Submit your updates here. ›

An extreme close-up of complex, interlocking metal and plastic components that make up Boston Scientific's medical devices, conveying the company's technological sophistication and industrial might.Boston Scientific's advanced medical technology is the backbone of its global business, as seen in this close-up of the company's precision manufacturing.Boston Today

Wall Street analysts forecast that Boston Scientific (BSX) will report quarterly earnings of $0.80 per share, up 6.7% year-over-year, on revenues of $5.19 billion, an 11.2% increase. However, the consensus EPS estimate has been revised down 0.4% over the last 30 days. Beyond the headline numbers, analysts have projections for several of Boston Scientific's key business segments and geographic regions.

Why it matters

Analyzing a company's performance across multiple metrics provides a more comprehensive view of its overall health and trajectory. This is especially important for complex, diversified firms like Boston Scientific that operate in various medical device markets. Scrutinizing these detailed projections can offer investors a clearer picture of the company's strengths, weaknesses, and growth opportunities.

The details

Analysts expect Boston Scientific's Cardiovascular division to see 12.9% year-over-year growth in worldwide net sales to $3.48 billion. The MedSurg segment, which includes Neuromodulation, Urology, and Endoscopy, is projected to grow 3.6% to $1.63 billion. Within Cardiovascular, the Electrophysiology and Watchman product lines are expected to post the strongest growth at 21.5% and 23.3% respectively. Geographically, the company's U.S. revenue is forecast to rise 11% to $3.28 billion, while the Rest of World segment is expected to grow 10.9% to $1.89 billion.

  • Boston Scientific is scheduled to report Q1 2026 earnings on April 17, 2026.

The players

Boston Scientific

A major medical device company that develops and manufactures a variety of products for the cardiovascular, neuromodulation, urology, and endoscopy markets.

Zacks Equity Research

The research division of Zacks Investment Research, a leading provider of stock research and analysis.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Boston Scientific's Q1 2026 earnings report on April 17, 2026 to see if the company can meet or exceed the analyst projections across its key business segments and geographic regions.

The takeaway

Analyzing a diversified medical device company like Boston Scientific requires looking beyond just the top and bottom line numbers. Digging into projections for specific product lines, business units, and regional performance provides a more holistic view of the company's overall health and growth trajectory.